Neuroblastoma
Conditions
Keywords
GSL synthetase inhibitor, GM-SCF
Brief summary
This exploratory clinical study will evaluate the efficacy and feasibility of combining a GSL synthase inhibitor with a granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced or metastatic neuroblastoma. Six to eight eligible patients are expected to be treated in this clinical trial: 1) Assessing the anti-tumour effects of GSL synthase inhibitors in combination with immune checkpoint inhibitors and/or GM-CSF; 2) To assess immunological or clinical predictive biomarkers of efficacy and toxicity; and 3) Detecting changes in the tumour microenvironment (TME) and the dynamics of peripheral blood immune cells after treatment with a GSL synthase inhibitor combined with GM-CSF.
Detailed description
Neuroblastoma is the most common extracranial solid tumour in infants and children. It is also known as an immunocold tumour due to the poor infiltration of immune cells in the tumour microenvironment. Tumour-associated macrophages and myeloid-derived suppressor cells account for a significant proportion of neuroblastoma cases and predominantly exert a pro-tumourigenic effect due to the tumour-suppressive microenvironment. Anti-phagocytic signals expressed by tumour cells, such as CD47, inhibit the direct cytophagy of macrophages. Patients in the high-risk group are less immunogenic and therefore less responsive to immune-checkpoint inhibitor (ICI) monotherapy than those in the low- and intermediate-risk groups. A combination of approaches may therefore be required for the immunotherapy of neuroblastoma. Aberrant expression of glycosphingolipid (GSL) synthase is a fundamental feature of most tumours and tumour microenvironments. Neurological tumours, including neuroblastoma, have been observed to exhibit elevated levels of acidic glycosphingolipids on their surfaces. A number of studies have indicated that there is an increase in the expression of GSL synthase in tumours that are resistant to chemotherapy. Eliglustat, an oral GlcCer synthase inhibitor, has been approved for the treatment of Gaucher disease type 1. Researchers have demonstrated the excellent safety and efficacy of Eliglustat in combination with immune checkpoint inhibitors for treating advanced/metastatic solid tumours and relapsed/refractory haematological malignancies. For these reasons, an exploratory clinical study was designed to observe the efficacy and feasibility of GSL synthase inhibitors in combination with GM-CSF in the treatment of patients with advanced/metastatic neuroblastoma. The objective of this study was to provide a high level of evidence-based rationale for the combination treatment regimen in these patients. The investigators will administer a combination of Eliglustat and GM-CSF to six patients diagnosed with advanced or metastatic NB. The primary objective of this study is to assess the efficacy and feasibility of Eliglustat in combination with GM-CSF in the treatment of neuroblastoma. The secondary objectives are to assess immunological or clinically predictive biomarkers of efficacy and toxicity, alterations in the tumour microenvironment, and changes in the dynamics of immune cells in the peripheral blood.
Interventions
DRUGEliglustat
Drug: GM-CSF + Eliglustat Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and GSL Synthetase Inhibitor
Sponsors
Chinese PLA General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
1. Neuroblastoma must be documented at the point of diagnosis, which is defined as one of the following: histopathology of a biopsy of a solid tumour; bone marrow aspirate or biopsy suggestive of neuroblastoma with elevated blood or urine catecholamine metabolite levels. 2. The participant is at least 6years old at time of enrollment. 3. At least one measurable lesion at baseline according to RECIST version 1.1. 4. Have adequate organ function as assessed by the laboratory required by protocol, which should be confirmed within 2 weeks prior to the first dose of study drugs. 5. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to \<= grade 1 toxicity. 6. Eastern Cooperative Oncology Group (ECOG) performance status score≤2 and Estimated life expectancy of more than 3 months. 7. Patient(and/ or their parent/ legal guardian) is willing to participate and able to provide signed informed consent.
Exclusion criteria
1. Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF 2. Existing major organ dysfunction \> Grade 2, with the exception of hearing loss, hematological status, kidney and liver function 3. Active life-threatening infection 4. History of allergy or intolerance to study drug components. 5. The participant is CYP2D6 ultra-rapid metabolizer. 6. The participant is known to be allergy to Eliglustat. 7. The participant use drugs that will strongly inhibit CYP2D6 or CYP3A activity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Up to 120 days after the last dose of study drugs | Objective response rate includes complete response and partial response defined by investigators according to RECIST 1.1or iRECIST criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Up to 2 years | Time from the date of first administration of the study drug to disease progression or death from any cause (any earliest date). |
| Overall Survival (OS) | Up to 2 years | Time from the date of first administration of the study drug to the date of death. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immunological response (cytokines, lymphocyte phenotype) | Up to 120 days after the last dose of study drugs | Following the administration of treatment, alterations in the concentrations of cytokines (primarily nitric oxide synthase (iNOS), interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNFα)) in picograms per millilitre (pg/mL)) will be evaluated in both the tumour bed and peripheral blood. Additionally, shifts in macrophage phenotypes (mainly encompassing the number and percentage of M1 and M2 cells) will be analysed using quantitative polymerase chain reaction (qPCR) and flow cytometry. |
| Biomarkers predictive of response and toxicity | Up to 120 days after the last dose of study drugs | Biomarkers from tumor cells, macrophages and tumor microenvironment will be assessed for their potential in predicting clinical response and toxicity.All participants with treatment-related adverse events (AE) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Event, Version 5.0(CTC AE 5.0). |
Countries
China
Contacts
Primary ContactWeidong Han, Ph.D
Backup ContactChen Feng
Outcome results
None listed